President & Chief Executive Officer
Gerri Henwood has served as our President and Chief Executive Officer and a director of the Company since 2019. Ms. Henwood also serves as the President and Chief Executive Officer and a director of Recro Pharma, Inc., a company she founded in 2008. From 2006 to 2013, Ms. Henwood served as the President of Malvern Consulting Group, Inc., or MCG, a pharmaceutical incubator and consulting firm. From 1999 to 2006, Ms. Henwood was the President and Chief Executive Officer of Auxilium Pharmaceuticals, Inc., or Auxilium, a biopharmaceutical company she founded in late 1999. From 1985 to 1999, Ms. Henwood was the founder and Chief Executive Officer of IBAH, Inc., or IBAH, a contract research organization. Ms. Henwood began her career with Smith Kline & French, now part of GlaxoSmithKline plc. She rose through the ranks to be a brand manager, then the head of Regulatory and Medical Affairs for the U.S. business and then to the position of Group Director—Marketing in the International Pharmaceutical Division.
Ms. Henwood currently serves on the board of directors of Tetraphase Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, a position she has held since May 2015. She previously served on the board of directors of Alkermes, Inc. and its successor company, Alkermes, plc, a global biopharmaceutical company, from 2003 until March 2015, and on the board of directors of MAP Pharmaceuticals, Inc., a biopharmaceuticals company, from 2004 until its acquisition by Allergan, Inc. in March 2013. Ms. Henwood also serves on the compensation committee of the board of directors of Tetraphase Pharmaceuticals, Inc.
Ms. Henwood holds a B.S. in Biology from Neumann University.
Ryan D. Lake
Chief Financial Officer
Mr. Lake has served as our Chief Financial Officer since the Company’s formation in 2019, and has over 20 years of senior financial and life sciences leadership experience. He also currently serves as the Chief Financial Officer for Recro Pharma, Inc. Mr. Lake joined Recro in June 2017 as the Chief Accounting Officer and Senior Vice President of Finance, before becoming CFO in January 2018. Before joining Recro, Mr. Lake served as Chief Financial Officer and Vice President of Finance of Aspire Bariatrics, Inc., a privately held, commercial-stage, medical device company. From 2012 to 2015, Mr. Lake held executive management and senior finance positions, including Director of the Natural Materials Division, Controller and Senior Director of Finance, at DSM Biomedical (successor to Kensey Nash after its acquisition in 2012), a division of Royal DSM (listed on Euronext Amsterdam), a global science-based company active in health, nutrition and materials. From 2002 to 2012, Mr. Lake held various senior financial positions of increasing responsibility, most notably Senior Director of Finance and Interim CFO, with Kensey Nash Corporation, a Nasdaq-listed, medical device company.
Earlier in his career, Mr. Lake worked at Deloitte & Touche, LLP. Mr. Lake is a Certified Public Accountant, Chartered Global Management Accountant and holds a B.S. degree in Accounting from West Chester University of Pennsylvania.
Chief Commercial Officer
John Harlow is our Chief Commercial Officer and has over 20 years of branded pharmaceutical experience, including commercial leadership roles in marketing, sales and operations. Before his role at Baudax Bio, he served as the Executive Vice President of Commercial at Recro Pharma from February 2018 to November 2019. He joined Recro Pharma as the Vice President of Marketing in October 2016. From 2015 to 2016, Mr. Harlow served as the Vice President & General Manager of the Pain Business Unit for Endo Pharmaceuticals. Before Endo, Mr. Harlow spent over three years at Shionogi in roles of increasing responsibilities including Vice President, Sales and Marketing and Vice President of Sales, Training and Operations. Before joining Shionogi, Mr. Harlow was a Senior Director of Marketing at King Pharmaceuticals where he oversaw the pain portfolio that was ultimately acquired by Pfizer. Mr. Harlow spent over six years with Novartis Pharmaceuticals in sales management and marketing leadership roles in the Neuroscience business unit.
Earlier in his career, Mr. Harlow was an equity research analyst at Merrill Lynch and a sales representative at Janssen Pharmaceuticals - a Johnson and Johnson company. He earned a B.S. in Biology from Lehigh University and an M.B.A. in Pharmaceutical Management & Marketing from The Stillman School of Business at Seton Hall University.
Stewart McCallum, MD
Chief Medical Officer
Stewart McCallum, M.D. serves as our Chief Medical Officer, previously serving as the Recro Pharma, Inc CMO from December 2015 to November 2019. From 2006 to 2015, Dr. McCallum worked at GlaxoSmithKline plc (GSK), a research-based pharmaceutical and healthcare company. While at GSK he served in a range of roles in discovery and development and ultimately as Clinical Director of the Academic and Sirtuin, Discovery Performance Units. During his time at GSK, Dr. McCallum successfully led high profile drug development programs across a wide variety of therapeutic areas including urology, oncology, gastroenterology, dermatology, stem cell therapies, in vitro fertilization and women’s health. While at GSK he was responsible for the planning, design and execution of comprehensive development plans incorporating medical, regulatory and commercial considerations.
From 1998 to 2006, Dr. McCallum served as an Assistant Professor of Urology at Stanford University Medical Center and the VA Palo Alto Health Care System. Dr. McCallum received his M.D. from the University of Toronto and his B.S. in Biochemistry from the University of Western Ontario. He completed his residency in Urology at the University of Toronto and a Clinical Fellowship in Microsurgery and Male Infertility at the Weill Cornell Medical College at New York-Presbyterian Hospital.
Dr. McCallum is a Certified Diplomat of the American Board of Urology; Fellow of the American College of Surgeons, and Fellow of the Royal College of Surgeons Canada.
Senior Vice President, Development
Randall Mack serves as our Senior Vice President, Development. Before his role at Baudax Bio, Mr. Mack was the SVP of Development at Recro Pharma from 2008 to November 2019. From 2008 to 2014, Mr. Mack served as Executive Vice President, Development for MCG, a pharmaceutical incubator and consulting firm. From 2005 to 2008, Mr. Mack served as Vice President, Project Management and Operations at Adolor Corporation where he oversaw the development programs in the areas of opioid-induced bowel dysfunction and pain management. For more than 15 years, he also held positions of increasing responsibilities at Auxilium, Abbott Laboratories and Harris Laboratories. In these positions, he was responsible for the conduct of over 400 clinical trials and the filing of 20 INDs and 4 NDAs.
During his career, Mr. Mack has authored more than 75 scientific articles, book chapters, abstracts and poster presentations in the areas of gastroenterology, urology, neuroscience and psychiatric disorders. Mr. Mack holds a B.S. in Biology and Chemistry from the University of Nebraska-Lincoln.
Senior Vice President, Regulatory & Quality
Diane Myers serves as the Senior Vice President, Regulatory and Quality. Before her role at Baudax Bio, she served as the Senior Vice President, Regulatory and Quality at Recro Pharma from 2008 to November 2019. From 2008 to 2014, Ms. Myers also served as Senior Vice President of Regulatory Affairs and Quality Assurance for MCG, a pharmaceutical incubator and consulting firm. From 2000 to 2008, Ms. Myers served as Vice President of Regulatory Affairs and Quality at Auxilium. In addition, for more than 15 years she held positions of increasing responsibility at GlaxoSmithKline plc in the Quality Control and Quality Assurance groups within the Biopharmaceutical Research and Development Division.
Ms. Myers holds a B.S. in Biology from Neumann University.
Jyrki Mattila, M.D., Ph.D.
Executive Vice President of Business Development
Dr. Mattila serves as our Executive Vice President, Business Development. He was previously the Executive Vice President, Business Development at Recro Pharma from August 2017 to November 2019. Before his time at Recro, Mr. Mattila served as Chief Business Officer at Lipocine Inc., a specialty pharmaceutical company, from 2010 to 2015, Dr. Mattila held executive management positions, serving as Chief Business Officer at iCeutica Inc. and as President and Chief Executive Officer at LZ Therapeutics, Inc. From 2003 to 2010, Dr. Mattila served as Executive Vice President, Business Development, Product Development and Technical Operations, at Auxilium Pharmaceuticals Inc., where he contributed to Auxilium’s growth from a private start-up to a publicly-traded specialty pharmaceutical company. From 1986 to 2003, Dr. Mattila held positions of increasing responsibility at Orion Corporation in business development, R&D and executive general management.
Dr. Mattila served as a Post-Doctoral Research Fellow at the University of Kansas Medical Center and holds an M.B.A. from the Helsinki School of Economics, a Ph.D. from the Department of Pharmacology at the University of Helsinki and an M.D. from the University of Helsinki Medical Schooll.